Pigment epithelium-derived factor is associated with... : Coronary Artery Disease (original) (raw)

Original Research

Pigment epithelium-derived factor is associated with necrotic core progression during statin therapy

Nozue, Tsuyoshi; Yamagishi, Sho-ichi; Hirano, Tsutomu; Yamamoto, Shingo; Tohyama, Shinichi; Fukui, Kazuki; Umezawa, Shigeo; Onishi, Yuko; Kunishima, Tomoyuki; Hibi, Kiyoshi; Terashima, Mitsuyasu; Michishita, Ichiro

aDivision of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital

bDepartment of Cardiology, Tsurumi Nishiguchi Hospital

cDepartment of Cardiology, Yokohama Seamen’s Insurance Hospital

dDepartment of Cardiology, Kanagawa Cardiovascular and Respiratory Center

eDivision of Cardiology, Yokohama City University Medical Center, Yokohama

fDepartment of Pathophysiology and Therapeutic of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume

gFirst Department of Internal Medicine, Showa University School of Medicine, Tokyo

hDepartment of Cardiology, Hiratsuka Kyosai Hospital, Hiratsuka

iFourth Department of Internal Medicine, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki

jCardiovascular Imaging Center, Toyohashi, Japan

Correspondence to Tsuyoshi Nozue, MD, Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, Yokohama 247-8581, Japan Tel: +81 45 891 2171; fax: +81 45 895 8352; e-mail: [email protected]

Received July 30, 2014

Received in revised form October 1, 2014

Accepted October 2, 2014

Abstract

Objective

Pigment epithelium-derived factor (PEDF) is a potent inhibitor of angiogenesis and an important target molecule for preventing the progression of atherosclerosis. However, the relationship between PEDF and coronary atherosclerosis has not been fully examined. The aim of the present study is to evaluate the effects of statins on serum PEDF levels and the association between PEDF and coronary atherosclerosis.

Patients and methods

Coronary atherosclerosis in nonculprit lesions in the vessel of patients undergoing a percutaneous coronary intervention was evaluated using virtual histology intravascular ultrasound in 99 patients during percutaneous coronary intervention and after 8 months of statin therapy.

Results

Serum PEDF levels at baseline and at the 8-month follow-up did not differ. A significant decrease in the fibro-fatty component (−0.24 mm3/mm, _P_=0.0003) and increases in the necrotic core (0.13 mm3/mm, _P_=0.02) and dense calcium components (0.11 mm3/mm, P<0.0001) were observed during the 8-month statin therapy. On univariate regression analyses, serum PEDF levels (_r_=0.291, _P_=0.004) and unstable angina pectoris (_r_=0.203, _P_=0.04) showed significant positive correlations with the percentage change in necrotic core volume. Multivariate regression analysis showed that serum PEDF level was a significant independent predictor associated with necrotic core progression during statin therapy (_β_=0.218, _P_=0.04).

Conclusion

Statin therapy had no effects on serum PEDF levels. Serum PEDF was a useful biomarker for predicting necrotic core progression during statin therapy, and its levels could be elevated as a counter-regulatory response mechanism to protect against necrotic core progression.